Edwards Lifesciences (NYSE:EW) Hits New 12-Month High After Analyst Upgrade

Edwards Lifesciences Corporation (NYSE:EW)’s share price hit a new 52-week high on Tuesday after BTIG Research raised their price target on the stock from $100.00 to $110.00. BTIG Research currently has a buy rating on the stock. Edwards Lifesciences traded as high as $92.88 and last traded at $91.3310, with a volume of 3606234 shares changing hands. The stock had previously closed at $90.78.

Several other analysts have also recently weighed in on EW. Mizuho set a $95.00 price objective on shares of Edwards Lifesciences and gave the stock an “outperform” rating in a research note on Monday, April 13th. Canaccord Genuity Group set a $85.00 target price on Edwards Lifesciences and gave the stock a “hold” rating in a report on Friday, April 24th. TD Cowen reissued a “buy” rating and issued a $104.00 target price (up from $97.00) on shares of Edwards Lifesciences in a report on Tuesday, June 2nd. Truist Financial set a $90.00 price target on Edwards Lifesciences and gave the company a “hold” rating in a report on Friday, April 24th. Finally, Wolfe Research upgraded Edwards Lifesciences from a “peer perform” rating to an “outperform” rating and set a $92.00 price objective for the company in a research report on Wednesday, April 1st. Three investment analysts have rated the stock with a Strong Buy rating, sixteen have assigned a Buy rating and eight have issued a Hold rating to the company. According to MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $96.39.

Insider Activity at Edwards Lifesciences

In other news, CFO Scott B. Ullem sold 13,000 shares of Edwards Lifesciences stock in a transaction on Thursday, April 9th. The stock was sold at an average price of $80.04, for a total value of $1,040,520.00. Following the completion of the sale, the chief financial officer directly owned 39,699 shares of the company’s stock, valued at approximately $3,177,507.96. This trade represents a 24.67% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, SVP Andrew M. Dahl sold 568 shares of the business’s stock in a transaction on Friday, May 29th. The stock was sold at an average price of $86.08, for a total value of $48,893.44. Following the sale, the senior vice president owned 15,334 shares of the company’s stock, valued at approximately $1,319,950.72. The trade was a 3.57% decrease in their position. The SEC filing for this sale provides additional information. In the last ninety days, insiders sold 58,977 shares of company stock worth $4,921,803. 0.31% of the stock is currently owned by company insiders.

Institutional Inflows and Outflows

A number of large investors have recently added to or reduced their stakes in EW. Hanson & Doremus Investment Management acquired a new stake in shares of Edwards Lifesciences during the 1st quarter worth approximately $25,000. JPL Wealth Management LLC acquired a new position in Edwards Lifesciences in the third quarter valued at approximately $25,000. MV Capital Management Inc. bought a new position in Edwards Lifesciences in the fourth quarter valued at approximately $26,000. RMG Wealth Management LLC acquired a new stake in Edwards Lifesciences during the 1st quarter worth $26,000. Finally, Kemnay Advisory Services Inc. acquired a new stake in Edwards Lifesciences during the 4th quarter worth $27,000. 79.46% of the stock is currently owned by institutional investors and hedge funds.

Edwards Lifesciences Stock Up 1.7%

The firm’s 50-day simple moving average is $85.06 and its 200 day simple moving average is $83.41. The company has a market cap of $52.95 billion, a P/E ratio of 48.91, a PEG ratio of 2.27 and a beta of 0.85. The company has a debt-to-equity ratio of 0.06, a quick ratio of 3.63 and a current ratio of 4.42.

Edwards Lifesciences (NYSE:EW) last posted its quarterly earnings results on Thursday, April 23rd. The medical research company reported $0.78 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.73 by $0.05. Edwards Lifesciences had a return on equity of 15.19% and a net margin of 17.39%.The business had revenue of $1.65 billion for the quarter, compared to analyst estimates of $1.60 billion. During the same period last year, the company earned $0.64 EPS. The firm’s revenue was up 16.7% on a year-over-year basis. Edwards Lifesciences has set its FY 2026 guidance at 2.950-3.050 EPS and its Q2 2026 guidance at 0.700-0.760 EPS. On average, research analysts forecast that Edwards Lifesciences Corporation will post 3 earnings per share for the current fiscal year.

Edwards Lifesciences Company Profile

Edwards Lifesciences is a medical technology company focused on products and therapies for structural heart disease and critical care monitoring. The company designs, develops and manufactures prosthetic heart valves and related delivery systems used in both surgical and minimally invasive (transcatheter) procedures. Its portfolio addresses a range of valvular conditions, with an emphasis on technologies that enable transcatheter aortic valve replacement (TAVR) as an alternative to open-heart surgery.

In addition to transcatheter heart valves—including the widely recognized SAPIEN family—Edwards offers surgical tissue valves and ancillary devices used by cardiac surgeons, interventional cardiologists and hospital teams.